Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).

Inclusion Criteria: * Men aged 19 to 50 years * Body weight 55 to 90 kg and BMI 18.0 to 27.0 * Voluntarily signed the informed consent form * Eligible according to the screening test results * Available to follow up after drop-out Exclusion Criteria: * Clinically significant disorders or a medical history of hepatic, renal, neurological, respiratory, endocrine, hemato-oncologic, cardiovascular, urological and psychiatric diseases * Hypersensitivity to donepezil, piperidine derivatives and other drugs * SBP \<100 mmHg or \>150 mmHg, or DBP \<60 mmHg or \>100 mmHg * Skin and muscle disorders or history of surgery at the injection site * AST or ALT \>1.5xULN; QT/QTcB interval \>450 ms * History or positive result of drug abuse * Prescribed drugs or herbal medicines within 2 weeks, over-the-counter drugs or vitamins within 1 week * Participated in other clinical trials within 3 months * Donated whole blood within 2 months or apheresis within 1 month, or transfusion within 1 month * Alcohol consumption \>21 units/week * Smoked \>10 cigarettes/day within 3 months * Caffeine-containing foods * Not eligible due to other reasons at the investigator's discretion